Browsing by Author "Snowdon, GM"
Now showing 1 - 2 of 2
Results Per Page
- ItemDevelopment of an exchange-labelling procedure and investigation of the radiochemical stability and biodistribution characteristics for (131I) meta-iodobenzylguanidine sulphate (131I) MIBG(Australian Nuclear Science and Technology Organisation, 1989-08) Jenkinson, AV; Maddalena, DJ; Snowdon, GM; Sorby, PJA simple exchange-labelling procedure for the radioiodination of meta-lobobenzylguanidine (MIBG) has been developed which facilitates the production of (131I) MIBG both quickly and efficiently. Stability studies indicate that labelled material if stored at reduced temperature undergoes little breakdown. Comparative biodistribution studies with a commercial source has been used to authenticate both the identity and purity of the product.
- ItemThe development of dysprosium-165 hydroxide macroaggregates for radiation synovectomy(Australian Nuclear Science and Technology Organisation, 1988-06) McLaren, AB; Hetherington, ELR; Maddalena, DJ; Snowdon, GMThe development of a dysprosium-165 product Dy-HMA which is suitable for the radiation synovectomy of arthritic joints is described. Dysprosium-165 is a short-lived (t 1 /2 = 139 min) β-emitter produced by the neutron irradiation of natural dysprosium. Dy-HMA is a suspension of macroaggregated hydroxide particles in saline with the majority of particles in the 3-5 um range. Studies in rabbits have demonstrated minimal leakage following the intra-articular injection of a knee joint. At 24 hours the accumulation in the liver is about 0.003% of the injected dose and there is considerably less in other organs and tissue. The use of Dy-HMA has considerable advantages over the presently used yttrium-90 products. The undesired leakage to and subsequent irradiation of other organs is considerably reduced. The period of hospitalisation is reduced from four days to one and the production of 165 Dy in Australia will overcome the difficulties of supply 90Y from overseas.